Bristol Myers Squibb FDA approval for multiple myeloma treatment
BRKSBMYMA9-060
Statements (6)
- Bullish
Small-molecule kinase inhibitors targeting ULK3 are effective in treating multiple myeloma.
- Bullish
Bristol Myers Squibb's stock is likely to rise significantly following the FDA approval of its novel multiple myeloma treatment.
- Neutral
FDA approves Bristol Myers Squibb oral treatment for advanced multiple myeloma
- Bullish
Bristol Myers Squibb received FDA approval for Myeloma treatment in combination with daratumumab, hyaluronidase-fihj, and dexamethasone.
- Bullish
Bristol Myers Squibb shares are likely to rise following the FDA approval of Zenbexus for myeloma treatment.
- Bullish
Bristol Myers Squibb sales of newer drugs like heart medicine drove strong results